Haematological and Bone Marrow Cancers
are looking at
Haematological cancers are cancers which affect the blood, bone marrow and lymph nodes. The most common types include leukaemias, lymphomas, myelomas and myeloproliferative disorders (MPDs). All affect cell types that are important for regulating the activity of the immune system.
Leukaemias start in blood-forming tissue such as the bone marrow and results in the release of large numbers of abnormal blood cells into the bloodstream. Leukaemias may be classed as acute or chronic and may stem from lymphocytic or myeloid cells. This equates to four subtypes; acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).
Lymphomas impact on lymphocytes and presents as a solid tumour that generally develops in the lymph nodes, spleen, bone marrow or blood. There are two subtypes, Hodgkin lymphoma and non-Hodgkin’s lymphoma. Myelomas lead to an accumulation of plasma cells in bone marrow which impacts on the production of normal blood cells.
Related news and insights
AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) announced topline results from the Phase III MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML).
Sobi and Sanofi announced that the XTEND-Kids phase III pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in previously treated patients under 12 years of age with severe haemophilia A met its primary endpoint
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...